The Effect of Aspirin to Reduced Incidence of Hepatocellular Carcinoma
A Comprehensive Systematic Review
Keywords:
aspirin, incidence, hepatocellular carcinoma, liver cancerAbstract
Background: Consistent aspirin usage is linked to a lower incidence of HCC in both the general population and certain populations that are at higher risk for the disease. Aspirin may also lessen the chance of HCC recurrence. Methods: This systematic review focused on full-text English literature published between 2014 and 2024 using the PRISMA 2020 guidelines. Editorials and review pieces published in the same journal as the submission without a DOI were not accepted. The literature was compiled using PubMed, ScienceDirect, and SagePub, among other online venues. Result: Five publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: The use of aspirin has been linked to a significant, duration-dependent reduction in the risk of incident HCC. Therefore, to determine the clinical effectiveness and safety of aspirin usage for HCC chemoprophylaxis, it is imperative to conduct randomised placebo-controlled studies in well-phenotyped groups.
References
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):2011–30.
Heimbach JK, kulik LM, Finn RS, Sirlin CB. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.
Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust. 2021;
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. JAMA Oncol. 2018 Nov 1;4(11):1553–68.
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Vol. 122, Cancer. John Wiley and Sons Inc.; 2016. p. 1312–37.
Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59(5):1135–8.
Singal AG, Pillai A, Tiro J. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. PLoS Med. 2014;11–4.
Shin S, Lee SH, Lee M. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Medicine (Baltim). 2020;
Cao Y, Nishihara R, Wu K. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;
Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. 2019;39:114–45.
Simon TG, Wilechansky RM, Stoyanova S, Grossman A, ichtel LE, Lauer GM. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial. JAMA. 2024;331(11):920–9.
Shi T, Fujita K, Gong J. Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. Oncol Rep. 2020;44:457–68.
Liu YX, Feng JY, Sun MM. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacol Sin. 2019;
Luo X, Yang W, Ma Y, Simoon TG, Meyerhardt JA. Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and Women. Cancer Prev Res (Phila). 2020;13(8):707–14.
Lee TY, Hsu YC, Ho HJ, Lin JT, Chen YJ, Wu CY. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study. EClinicalMedicine. 2023;
Lu C De, Jiang YB, Feng JK, Wang L, Wei XB, Zhou B, et al. Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial. Heliyon. 2023 Sep 1;9(9).
Lee CH, Hsu CY, Yen TH, Wu TH, Yu MC, Hsieh SY. Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma and Overall Mortality in Patients with Cirrhosis. Cancers (Basel). 2023;15(11):2946.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Chrysman Andreria Hatulely , Daniel Setiawan Nathan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
